Joe Biden: I Know Firsthand the Toll of This Disease, Get Screened
FDA Approves Durvalumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer
Belzutifan Plus Lenvatinib Moves Closer to EU Approval for Advanced Kidney Cancer
YOGI Aims to Create New Opportunities for Young GI Oncologists Across Europe - CancerWorld
Anthropic CEO Dario Amodei: Can AI Cure Cancer by 2036?
One Procedure, Two Goals: Lung Biopsy and Cryoablation Show Promising Results in Early-Stage NSCLC
CALR-Mutated MPN: A Shared Neoantigen Makes Immunotherapy Possible, and Antibodies Lead So Far
UICC Wins Best International Association Award at the Association Excellence Awards 2026 in London
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
